First American Trust FSB decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 25.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,604 shares of the medical equipment provider’s stock after selling 28,771 shares during the period. First American Trust FSB’s holdings in Boston Scientific were worth $2,990,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of BSX. Parkwood LLC purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at about $6,250,000. Waddell & Reed Financial Inc. bought a new position in Boston Scientific during the 2nd quarter valued at about $5,559,000. Bellevue Group AG grew its holdings in Boston Scientific by 19.3% during the 3rd quarter. Bellevue Group AG now owns 978,929 shares of the medical equipment provider’s stock valued at $37,689,000 after purchasing an additional 158,333 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in Boston Scientific by 2.0% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 965,855 shares of the medical equipment provider’s stock valued at $31,583,000 after purchasing an additional 19,383 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in Boston Scientific by 3.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock valued at $1,671,000 after purchasing an additional 1,547 shares during the last quarter. 90.72% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:BSX traded down $0.39 during midday trading on Friday, reaching $35.56. The company’s stock had a trading volume of 5,488,648 shares, compared to its average volume of 6,991,511. The firm has a market capitalization of $49.65 billion, a P/E ratio of 28.22, a PEG ratio of 2.08 and a beta of 0.72. Boston Scientific Co. has a twelve month low of $25.04 and a twelve month high of $39.44. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.78 and a quick ratio of 0.56.
In other Boston Scientific news, SVP Desiree Ralls-Morrison sold 4,047 shares of Boston Scientific stock in a transaction dated Wednesday, January 9th. The shares were sold at an average price of $36.00, for a total transaction of $145,692.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Wendy Carruthers sold 1,500 shares of Boston Scientific stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $36.64, for a total transaction of $54,960.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 210,852 shares of company stock worth $7,683,664. Insiders own 0.73% of the company’s stock.
BSX has been the topic of a number of research analyst reports. Wells Fargo & Co upped their target price on shares of Boston Scientific from $38.00 to $42.00 and gave the stock an “outperform” rating in a research note on Monday, September 17th. Oppenheimer restated a “hold” rating on shares of Boston Scientific in a research note on Tuesday, September 25th. Morgan Stanley upped their target price on shares of Boston Scientific from $38.00 to $48.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 2nd. Royal Bank of Canada upped their target price on shares of Boston Scientific to $42.00 and gave the stock a “top pick” rating in a research note on Monday, October 15th. Finally, Barclays initiated coverage on shares of Boston Scientific in a research note on Monday, October 15th. They issued an “overweight” rating and a $43.00 target price on the stock. Three research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $40.12.
TRADEMARK VIOLATION NOTICE: This news story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2019/01/11/boston-scientific-co-bsx-shares-sold-by-first-american-trust-fsb.html.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
See Also: Stock Selection – What is cash flow?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.